+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Checkpoint Inhibitor Refractory Cancer - Epidemiology Forecast 2030

  • ID: 5387724
  • Drug Pipelines
  • July 2021
  • Region: Global
  • 200 pages
  • DelveInsight
This ‘Checkpoint-inhibitor Refractory Cancer - Epidemiology Forecast - 2030' report delivers an in-depth understanding of Checkpoint-inhibitor Refractory Cancer, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Checkpoint-inhibitor Refractory Cancer Disease Understanding

Over the last decade, a major achievement in cancer research has been introducing immune checkpoint inhibitors in treatment. Anti-PD1/PDL1 antibodies are among the most widely prescribed anticancer therapies. Checkpoint inhibitors are now used as single agents or combined with chemotherapies as first or second lines of treatment for about 50 cancer types.

In contrast to old cytotoxic therapies, immune checkpoint inhibitors augment the host immune system to fight cancer. Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body. However, when the checkpoint and partner proteins bind together in cancer, they send an “off” signal to the T cells preventing the immune system from destroying cancer.

Checkpoint-inhibitor Refractory Cancer Epidemiology

The Checkpoint-inhibitor Refractory Cancer epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total incident cases of Checkpoint-inhibitor Refractory Cancer patients are increasing in 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Checkpoint-inhibitor Refractory Cancer symptoms epidemiology segmented as the Incidence by tumor type, Checkpoint-inhibitor-treated patients and Checkpoint-inhibitor refractory patients. The report includes the incident scenario of Checkpoint-inhibitor Refractory Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Checkpoint-inhibitor Refractory Cancer Epidemiology

The epidemiology segment also provides the Checkpoint-inhibitor Refractory Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The incident cases of Checkpoint-inhibitor Refractory Cancer-associated in 7MM countries were 156,370 in 2020.
  • As per the estimates, the United States has the largest incident population of Checkpoint-inhibitor Refractory Cancer.
  • Among the EU5 countries, Germany had the highest incident cases of Checkpoint-inhibitor Refractory Cancer, followed by France. On the other hand, Spain had the lowest incident cases with 7,701 cases in 2020.
Scope of the Report
  • The Checkpoint-inhibitor Refractory Cancer report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Checkpoint-inhibitor Refractory Cancer Epidemiology Report and Model provide an overview of Checkpoint-inhibitor Refractory Cancer's risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into Checkpoint-inhibitor Refractory Cancer's historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Checkpoint-inhibitor Refractory Cancer.
  • The report provides the segmentation of the Checkpoint-inhibitor Refractory Cancer epidemiology by the incidence by tumor type in 7MM.
  • The report provides the Checkpoint-inhibitor Refractory Cancer epidemiology segmentation by Checkpoint-inhibitor-treated patients in 7MM.
  • The report provides the Checkpoint-inhibitor Refractory Cancer epidemiology segmentation by Checkpoint-inhibitor refractory patients in 7MM.
Report Highlights
  • 10-year Forecast of Checkpoint-inhibitor Refractory Cancer epidemiology
  • 7MM Coverage
  • Incidence by tumor type
  • Checkpoint-inhibitor treated patients
  • Checkpoint-inhibitor refractory patients
KOL Views

The publisher interviews KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM for the patient population about Checkpoint-inhibitor Refractory Cancer?
  • What are the key findings of the Checkpoint-inhibitor Refractory Cancer epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018-2030)?
  • What would be the total number of Checkpoint-inhibitor Refractory Cancer patients across the 7MM during the forecast period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2018-2030)?
  • What are the disease risk, burden, and unmet needs of Checkpoint-inhibitor Refractory Cancer?
  • What are the currently available treatments for Checkpoint-inhibitor Refractory Cancer?
Reasons to Buy

The Checkpoint-inhibitor Refractory Cancer epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Checkpoint-inhibitor Refractory Cancer market.
  • Quantify patient populations in the global Checkpoint-inhibitor Refractory Cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Checkpoint-inhibitor Refractory Cancer therapeutics in each of the markets covered.
  • Understand the magnitude of the Checkpoint-inhibitor Refractory Cancer population by tumor type incidence.
  • Understand the magnitude of the Checkpoint-inhibitor Refractory Cancer population by its treated patients.
  • Understand the magnitude of the Checkpoint-inhibitor Refractory Cancer population by its refractory patients.
  • The Checkpoint-inhibitor Refractory Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Checkpoint-inhibitor Refractory Cancer Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Based on the data from 2012 to 2016, as per the Centers for Disease Control and Prevention (CDC), new melanoma cases occurred in the United States each year, including 45,854 among men and 31,845 among women. Further, the overall incidence rate of melanoma was 21.8/100,000. Similarly, according to the National Cancer Institute's Surveillance, Epidemiology and End Results Program (SEER) (n.d.), the rate of new cases of melanoma of the skin was 22.7/100,000 men and women/year. While according to Globocan, almost 96,000 incident cases of melanoma were reported in 2020 in the United States.

Based on the latest GLOBOCAN data, BC accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. An estimated 550,000 people were diagnosed with bladder cancer in 2018. As per Saginala et al. (2020), nations with the highest BC rates are largely found in Southern and Western Europe and North America. The region with the highest rate of BCs among women in Southern Europe (same as among men), where an estimated 26.5/100,000 men and 5.5/100,000 women develop the disease every year. In many European nations, such as Germany and Bulgaria, incidence rates of bladder cancer have continued to rise and are expected to increase even further due to a greater prevalence of smoking and an aging population. According to Cancer Treatment Centers of America, an estimated 35% of patients with invasive CC develop persistent or recurrent disease following treatment.

Furthermore, as per CDC, all women are at risk for CC. It occurs most often in women over age 30. Each year, approximately 12,000 women in the United States get cervical cancer.
Note: Product cover images may vary from those shown
1 Key Insights

2 Report Introduction

3 Checkpoint-inhibitor Refractory Cancer Market Overview at a Glance
3.1 Patient Share (%) Distribution of Checkpoint-inhibitor Refractory Cancer in 2018
3.2 Patient Share (%) Distribution of Checkpoint-inhibitor Refractory Cancer in 2030

4 Executive Summary of Checkpoint-inhibitor Refractory Cancer

5 Disease Background and Overview
5.1 Introduction
5.2 Scientific Overview
5.3 Cancer-Immunity Cycle
5.4 Checkpoint blockade of the CTLA-4 pathway
5.5 Checkpoint blockade of the PD-1/PD-L1
5.6 Next-generation immune checkpoints for cancer therapy
5.7 Solid tumors
5.7.1 Urothelial Carcinoma
5.7.1.1 Diagnosis
5.7.1.2 Treatment
5.7.1.3 Guidelines for Bladder Cancer
5.7.1.4 The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.2 NSCLC
5.7.2.1 Pathogenesis
5.7.2.2 Diagnosis
5.7.2.3 Treatment
5.7.2.4 Guideline for NSCLC
5.7.1.1.1 The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021
5.7.1.1.2 The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.3 Melanoma
5.7.3.1 Pathophysiology
5.7.3.2 Diagnosis
5.7.3.3 Treatment
5.7.4 Renal cell carcinoma
5.7.4.1 Pathophysiology
5.7.4.2 Diagnosis
5.7.4.3 Treatment
5.7.4.4 Guidelines for Renal Cell Carcinoma
5.7.1.1.3 The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021
5.7.1.1.4 ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.5 Hodgkin Lymphoma
5.7.5.1 Pathophysiology
5.7.5.2 Diagnosis
5.7.5.3 Treatment
5.7.6 Breast Cancer
5.7.6.1 Pathophysiology
5.7.6.2 Diagnosis
5.7.6.3 Treatment
5.7.7 Cervical Cancer
5.7.7.1 Diagnosis
5.7.7.2 Treatment
5.7.7.3 Guidelines for Cervical Cancer
5.7.1.1.5 The National Comprehensive Cancer Network (NCCN) Clinical Guidelines: 2021
5.7.1.1.6 ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
5.7.8 Mesothelioma
5.7.8.1 Pathophysiology
5.7.8.2 Diagnosis
5.7.8.3 Treatment

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Population of Checkpoint-inhibitor refractory patients
6.3 Epidemiology of Checkpoint Inhibitors refractory cancer
6.4 The United States
6.4.1 Incidence by tumor type in the United States
6.4.2 Checkpoint-inhibitor treated patients in the United States
6.4.3 Checkpoint-inhibitor refractory patients in the United States
6.5 EU5
6.5.1 Germany
6.5.1.1 Incidence by tumor type in Germany
6.5.1.2 Checkpoint-inhibitor treated patients in Germany
6.5.1.3 Checkpoint-inhibitor refractory patients in Germany
6.5.2 France
6.5.2.1 Incidence by tumor type in France
6.5.2.2 Checkpoint-inhibitor treated patients in France
6.5.2.3 Checkpoint-inhibitor refractory patients in France
6.5.3 Italy
6.5.3.1 Incidence by tumor type in Italy
6.5.3.2 Checkpoint-inhibitor treated patients in Italy
6.5.3.3 Checkpoint-inhibitor refractory patients in Italy
6.5.4 Spain
6.5.4.1 Incidence by tumor type in Spain
6.5.4.2 Checkpoint-inhibitor treated patients in Spain
6.5.4.3 Checkpoint-inhibitor refractory patients in Spain
6.5.5 United Kingdom
6.5.5.1 Incidence by tumor type in the United Kingdom
6.5.5.2 Checkpoint-inhibitor treated patients in the United Kingdom
6.5.5.3 Checkpoint-inhibitor refractory patients in the United Kingdom
6.6 Japan
6.6.1 Incidence by tumor type in Japan
6.6.2 Checkpoint-inhibitor treated patients in Japan
6.6.3 Checkpoint-inhibitor refractory patients in Japan

8 Appendix
8.1 Bibliography
8.2 Report Methodology

9 Publisher Capabilities

10 Disclaimer

11 About the Publisher

List of Tables
Table 1: Summary of Checkpoint-inhibitor Refractory Cancer, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Recommendations for treatment-naive advanced or metastatic UC
Table 3: Summary of recommendations
Table 4: Summary of recommendations for immune and targeted therapy
Table 5: Systemic Therapy Regimens for Neoadjuvant and Adjuvant Therapy
Table 6: Concurrent Chemoradiation Regimens
Table 7: Targeted therapy or Immunotherapy for Advanced or Metastatic Disease
Table 8: Principles of Systemic Therapy
Table 9: Principles of systemic therapy for relapse or stage IV disease
Table 10: Systemic Therapy for Non-clear Cell Histology
Table 11: Systemic Therapy for cervical cancer
Table 12: Total Incident Population of Checkpoint-inhibitor refractory patients in 7MM(2018-2030)
Table 13: Incidence by tumor type in the United States (2018-2030)
Table 14: Checkpoint-inhibitor treated patients in the United States (2018-2030)
Table 15: Checkpoint-inhibitor refractory patients in the United States (2018-2030)
Table 16: Incidence by tumor type in Germany (2018-2030)
Table 17: Checkpoint-inhibitor treated patients in Germany (2018-2030)
Table 18: Checkpoint-inhibitor refractory patients in Germany (2018-2030)
Table 19: Incidence by tumor type in France (2018-2030)
Table 20: Checkpoint-inhibitor treated patients in France (2018-2030)
Table 21: Checkpoint-inhibitor refractory patients in France (2018-2030)
Table 22: Incidence by tumor type in Italy (2018-2030)
Table 23: Checkpoint-inhibitor treated patients in Italy (2018-2030)
Table 24: Checkpoint-inhibitor refractory patients in Italy (2018-2030)
Table 25: Incidence by tumor type in Spain (2018-2030)
Table 26: Checkpoint-inhibitor treated patients in Spain (2018-2030)
Table 27: Checkpoint-inhibitor refractory patients in Spain (2018-2030)
Table 28: Incidence by tumor type in the United Kingdom (2018-2030)
Table 29: Checkpoint-inhibitor treated patients in the United Kingdom (2018-2030)
Table 30: Checkpoint-inhibitor refractory patients in the United Kingdom (2018-2030)
Table 31: Incidence by tumor type in Japan (2018-2030)
Table 32: Checkpoint-inhibitor treated patients in Japan (2018-2030)
Table 33: Checkpoint-inhibitor refractory patients in Japan (2018-2030)

List of Figures
Figure 1: Cancer Immunity Cycle
Figure 2: CTLA-4 Immune checkpoint
Figure 3: PD-1 Immune checkpoint
Figure 4: Total Incident Population of Checkpoint-inhibitor refractory patients in 7MM in 000’s (2018-2030)
Figure 5: Incidence by tumor type in the United States in 000s (2018-2030)
Figure 6: Checkpoint-inhibitor treated patients in the United States in 000s (2018-2030)
Figure 7: Checkpoint-inhibitor refractory patients in the United States in 000s (2018-2030)
Figure 8: Incidence by tumor type in Germany in 000s (2018-2030)
Figure 9: Checkpoint-inhibitor treated patients in Germany in 000s (2018-2030)
Figure 10: Checkpoint-inhibitor refractory patients in Germany in 000s (2018-2030)
Figure 11: Incidence by tumor type in France in 000s (2018-2030)
Figure 12: Checkpoint-inhibitor treated patients in France in 000s (2018-2030)
Figure 13: Checkpoint-inhibitor refractory patients in France in 000s (2018-2030)
Figure 14: Incidence by tumor type in Italy in 000s (2018-2030)
Figure 15: Checkpoint-inhibitor treated patients in Italy in 000s (2018-2030)
Figure 16: Checkpoint-inhibitor refractory patients in Italy in 000s (2018-2030)
Figure 17: Checkpoint-inhibitor treated patients in Spain in 000s (2018-2030)
Figure 18: Checkpoint-inhibitor refractory patients in Spain in 000s (2018-2030)
Figure 19: Incidence by tumor type in the United Kingdom in 000s (2018-2030)
Figure 20: Checkpoint-inhibitor treated patients in the United Kingdom in 000s (2018-2030)
Figure 21: Checkpoint-inhibitor refractory patients in the United Kingdom in 000s (2018-2030)
Figure 22: Incidence by tumor type in Japan in 000s (2018-2030)
Figure 23: Checkpoint-inhibitor-treated patients in Japan in 000s (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll